AllianceBernstein’s Astria Therapeutics ATXS Stock Holding History

AllianceBernstein’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,732,464	Closed	-$22.7M	–	3233
2025 Q4	$22.7M	Buy	1,732,464 +1,674,494	+2,889%	+$20M	0.01%	898
2025 Q3	$422K	Hold	57,970	–	–	﹤0.01%	2769
2025 Q2	$311K	Buy	57,970 +3,950	+7%	+$19.1K	﹤0.01%	2896
2025 Q1	$288K	Hold	54,020	–	–	﹤0.01%	2788
2024 Q4	$483K	Hold	54,020	–	–	﹤0.01%	2655
2024 Q3	$595K	Hold	54,020	–	–	﹤0.01%	2578
2024 Q2	$492K	Buy	54,020 +4,650	+9%	+$45.4K	﹤0.01%	2678
2024 Q1	$695K	Buy	+49,370	New	+$615K	﹤0.01%	2439

AllianceBernstein's ATXS Position: Q1 2026 in Review

AllianceBernstein sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 1,732,464 shares — an estimated $22.7M sold.

AllianceBernstein first reported a position in ATXS in Q1 2024 and held it in 8 quarters. The position peaked at $22.7M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

AllianceBernstein reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
AllianceBernstein sold 1,732,464 Astria Therapeutics shares in Q1 2026, an estimated $22.7M.
AllianceBernstein first reported a position in Astria Therapeutics in Q1 2024 and held it in 8 quarters.
AllianceBernstein's Astria Therapeutics position peaked at $22.7M in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.